NCT04206891
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: CDH1/3
Breast Cancer Tissue: Invasive lobular carcinoma (ILC)
Recruitment Status: Active, not recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have been diagnosed with lobular breast cancer at 45 years of age or younger
Exclusions: Patients with germline (hereditary) BRCA1/2 mutations
https://ClinicalTrials.gov/show/NCT04206891